Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (44)

2024

  1. Acyl-CoA binding protein for the experimental treatment of anorexia

    Science translational medicine, Vol. 16, Núm. 760, pp. eadl0715

  2. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  3. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

    European Journal of Heart Failure

  4. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  5. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 9, pp. 2132-2141

  6. Toxicity of zinc oxide nanoparticles: Cellular and behavioural effects

    Chemosphere, Vol. 363

  7. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1025-1048

  3. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  4. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry

    European journal of preventive cardiology, Vol. 30, Núm. 13, pp. 1346-1358

  5. Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 1061-1071

  6. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery

    European Journal of Heart Failure, Vol. 25, Núm. 12, pp. 2316-2330

  7. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2022

  1. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC-HFA EORP Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 335-350

  2. Carotid Ultrasound Boundary Study (CUBS): Technical considerations on an open multi-center analysis of computerized measurement systems for intima-media thickness measurement on common carotid artery longitudinal B-mode ultrasound scans

    Computers in Biology and Medicine, Vol. 144

  3. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

    American Heart Journal, Vol. 248, pp. 72-83

  4. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

  5. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  6. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4